The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The study protocol is a single-arm, open label pilot study designed to evaluate the impact of
PCSK-9 inhibition on coronary blood flow in patients with stable coronary artery disease.
Patients with stable coronary artery disease will be recruited from the BWH Cardiovascular
Medicine clinic and/or from the BWH Nuclear Cardiology Laboratory. A target sample size of 35
participants will undergo imaging with N-13 ammonia positron emission tomography (PET) and
coronary computed tomography angiography (CCTA) before and after 12 months of PCSK-9
inhibition with Evolocumab to assess changes in myocardial blood flow, plaque volume, and
vascular endothelial function.